SCHEDULE: RTW Investments Boosts Tarsus Stake to 8.1%

RTW Investments, LP and Roderick Wong, M.D. have reported a beneficial ownership of 8.1% in Tarsus Pharmaceuticals, Inc.

Summary

• RTW Investments, LP and its Managing Partner, Roderick Wong, M.D., collectively reported beneficial ownership of 3,424,180 shares of Tarsus Pharmaceuticals, Inc. Common Stock.
• This ownership represents 8.1% of the outstanding shares of Tarsus Pharmaceuticals, Inc.
• The percentage is calculated based on 42,014,237 shares outstanding as of April 24, 2025, as reported in the company's Form 10-Q.
• The shares are held by RTW Funds, for which RTW Investments acts as an investment adviser.
• The acquisition and holding of these securities are stated to be in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.

Sentiment

Score: 5

Explanation: The filing is a factual disclosure of beneficial ownership and does not contain information that would inherently indicate positive or negative sentiment regarding the company's performance or outlook.

Positives

• NA

Negatives

• NA

Risks

• NA

Future Outlook

NA

Industry Context

This filing indicates a significant institutional investment firm, RTW Investments, maintains a substantial stake in Tarsus Pharmaceuticals, Inc., a company operating in the biotechnology and pharmaceutical sector. Such ownership by specialized healthcare investors can signal confidence in the company's long-term prospects within the competitive pharmaceutical landscape.

Comparison to Industry Standards

• NA

Stakeholder Impact

• Shareholders may view the continued significant ownership by an institutional investor like RTW Investments as a sign of confidence in Tarsus Pharmaceuticals, Inc.

Key Dates

Keywords

Tarsus Pharmaceuticals, RTW Investments, Roderick Wong, Beneficial Ownership, SEC Filing, Common Stock, Investment Adviser, Biotechnology, Pharmaceuticals